Related Experiment Video

Updated: Aug 18, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

[Cyclooxygenase 2 inhibitors and colorectal cancer]

Marianne Bernardeau-Mozer1, Stanislas Chaussade

  • 1Service d'Hépato-gastroentérologie, Pavillon Achard 9, Hôpital Cochin, 27, rue du Faubourg Saint-Jacques, 75014 Paris.

Bulletin Du Cancer
|May 19, 2005
PubMed

Insights

Cyclooxygenase-2 (Cox2) is overexpressed in most colorectal tumors, driving cancer growth. Cox2 inhibitors show promise as chemopreventive and therapeutic agents for colorectal cancer management.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Context:

  • Cyclooxygenase-2 (Cox2) is an inducible enzyme.
  • Cox2 is undetectable in normal colonic mucosa but overexpressed in 80% of colorectal tumors.
  • Cox2 plays a critical role in colorectal tumorigenesis, including inhibiting apoptosis, promoting cellular proliferation, and inducing angiogenesis.

Purpose:

  • To review the relationship between Cox2 and its inhibitors and the signaling pathways involved in colorectal carcinogenesis.
  • To elucidate the molecular mechanisms of action of Cox2 inhibitors.
  • To review clinical data on the efficacy of Cox2 inhibitors in chemoprevention and therapy for colorectal cancer.

Summary:

  • Cox2 is a key molecular target in colorectal cancer management.
  • Cox2 inhibitors have demonstrated efficacy in animal studies.
  • Cox2 inhibitors are FDA-approved for specific patient groups, such as those with Familial Adenomatous Polyposis (FAP).

Impact:

  • Cox2 inhibitors represent a potential strategy for colorectal cancer chemoprevention and therapy.
  • Understanding the molecular mechanisms can lead to improved treatment protocols.
  • This review provides insights into the clinical efficacy of Cox2 inhibitors across different risk groups for colorectal cancer.

More Related Videos

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine06:24

Establishment of Coloproctitis Cancer Model in Mice and Evaluation of Therapeutic Effect of Chinese Medicine

Published on: October 13, 2023

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach10:01

Structure-Guided Design and Development of Novel Cyclophilin A Inhibitors and Ganoderiol-F Derivatives: An In-Silico Approach

Published on: June 23, 2026

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...